Cassava Sciences, Inc.

NasdaqCM SAVA

Cassava Sciences, Inc. Price to Book Ratio (P/B) on January 14, 2025

Cassava Sciences, Inc. Price to Book Ratio (P/B) is NA on January 14, 2025, a NA change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Cassava Sciences, Inc. 52-week high Price to Book Ratio (P/B) is NA on January 14, 2025, which is NA below the current Price to Book Ratio (P/B).
Cassava Sciences, Inc. 52-week low Price to Book Ratio (P/B) is NA on January 14, 2025, which is NA below the current Price to Book Ratio (P/B).
Cassava Sciences, Inc. average Price to Book Ratio (P/B) for the last 52 weeks is NA.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

NasdaqCM: SAVA

Cassava Sciences, Inc.

CEO	Mr. Richard Jon Barry
IPO Date	July 14, 2000
Location	United States
Headquarters	7801 North Capital of Texas Highway
Employees	29
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Key trends

Past 5 years